Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis


30 Sep 2019


Poster Display session 3


Tumour Site

Head and Neck Cancers


Jason Tasoulas


Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252


J. Tasoulas1, K. Divaris2, S. Theocharis3, D. Farquhar4, T. Hackman4, A.L. Amelio5

Author affiliations

  • 1 First Department Of Pathology, Medical School, National And Kapodistrian University Of Athens; Lineberger Comprehensive Cancer Center, Unc School Of Medicine; Department Of Oral And Craniofacial Health Sciences, Unc School Of Dentistry, National and Kapodistrian University of Athens; University of North Carolina at Chapel Hill; University of Thessaly, 11527 - Athens/GR
  • 2 Department Of Epidemiology, Gillings School Of Global Public Health; Department Of Pediatric Dentistry, Unc School Of Dentistry, University of North Carolina at Chapel Hill, 27599 - Chapel Hill/US
  • 3 First Department Of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 - Athens/GR
  • 4 Department Of Otolaryngology/head And Neck Surgery, University of North Carolina at Chapel Hill, 27599 - Chapel Hill/US
  • 5 Lineberger Comprehensive Cancer Center, Unc School Of Medicine; Department Of Oral And Craniofacial Health Sciences, Unc School Of Dentistry; Biomedical Research Imaging Center, Unc School Of Medicine, University of North Carolina at Chapel Hill, 27599 - Chapel Hill/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4887


Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor, comprising less than 1% of head and neck neoplasms. Adjuvant radiotherapy (aRT) is suggested for late-stage disease (stage III or IV); however, recent evidence suggests that it may be associated with improved survival even for early-stage disease. Moreover, the prognostic significance of tumor location on overall (OS) and ACC-specific (ACC-S) survival is unclear. We sought to address these knowledge gaps via analyses of the Surveillance, Epidemiology and End Results (SEER) database.


Intraoral minor (m) and major (M) ACCs from the SEER database (1973-2015) were selected for analysis. Information on age, sex, race, site, stage, treatment and survival was retrieved. The associations of tumor site and aRT with OS and ACC-S were estimated using hazard ratios (HR) and corresponding 95% confidence intervals (CI) obtained via Cox regression models adjusted for covariates as appropriate. Analyses were done using Stata 15.1 (StataCorp LP, College Station, TX).


There were 635 minor and 1,064 major (parotid: n = 547, submandibular: n = 470, sublingual: n = 47) ACC cases included in the analyses. Late-stage patients (49% of total) were significantly more likely to have received aRT (76% vs. 66%; P < 0.01) compared to those with early-stage disease. Submandibular was the only tumour site that demonstrated statistically significant survival differences compared to the other sites; i.e., worse OS (HR = 1.4; 95% CI = 1.1-1.8) and ACC-S (HR = 1.7; 95% CI = 1.2-2.3) compared to minor ACCs. This difference was only evident for late-stage tumours: stage IV submandibular cases had worse OS (HR = 2.1; 95% CI = 1.5-2.8) and ACC-S (HR = 2.4; 95% CI = 1.7-3.4) compared to stage IV minor ACCs. Overall, aRT was associated with better OS (HR = 0.7; 95% CI = 0.6-0.9) and ACC-S (HR = 0.8; 95% CI = 0.6-1.1). This beneficial effect was more pronounced and statistically confirmed only in stage IV disease.


These results, based on SEER data, suggest that aRT is associated with favorable survival only in late-stage ACC and that, among these late-stage tumors, submandibular gland ACCs have substantially worse prognosis than other sites, irrespective of aRT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Academy of Athens PhD Scholarship to Jason Tasoulas; UNC Lineberger Tier 3 Developmental Award funds and the University Cancer Research Fund to A.L. Amelio.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.